Category: MS Drug Therapies

3 Times a Week Dose Copaxone for Relapsing MS Receives Positive Outcome in Europe

Israel-based biopharmaceutical company Teva Pharmaceutical Industries Ltd. announced last week that its thrice-weekly COPAXONE® (glatiramer acetate)40mg/ml treatment for relapsing-remitting multiple sclerosis (RRMS) has received positive results…

Stuart Schlossman

HSE to fund on limited basis cost of multiple sclerosis drug

Extended campaign by patients proves success for medicine that helps sufferers to walk Patients have been paying up to €500…

Stuart Schlossman

Information on a New MS Treatment Option – ‘LEMTRADA’ live events start now

CLICK THE BANNER to find a program near you For more information on Lemtrada click: https://www.lemtrada.com/  . Visit our MS Learning…

Stuart Schlossman

Learning about an Oral Treatment Option

CLICK the above banner to find  MS events near you Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews…

Stuart Schlossman

Third Case of PML With Fingolimod (Gilenya) in MS

Novartis has been notified of a third case of progressive multifocal leukoencephalopathy (PML) in a patient with relapsing multiple sclerosis…

Stuart Schlossman

Copaxone sales Continue STRONG

UBS: Copaxone sales strong despite generic rivals UBS says, “The launch for generic Copaxone has not gone very well, with…

Stuart Schlossman

Novartis to Buy Multiple Sclerosis Drug From Glaxo

HONG KONG — Novartis bolstered its portfolio of multiple sclerosis treatments on Friday by agreeing to buy an experimental drug…

Stuart Schlossman

Gilenya (fingolimod): Drug Safety Communication – FDA Warns About Cases of Rare Brain Infection (PML)

August 4, 2015 ISSUE: FDA is warning that a case of definite progressive multifocal leukoencephalopathy (PML) and a case of…

Stuart Schlossman

Pfizer and Synthon Enter Into U.S. Commercialization Agreement for Potential Generic Treatment of Multiple Sclerosis

Synthon’s glatiramer acetate, a potential generic version of Copaxone®1 for the treatment of relapsing remitting multiple sclerosis is currently being…

Stuart Schlossman

Biogen’s Tecfidera Now The Most Prescribed Oral MS Therapy Globally

Cambridge, Massachusetts based Biogen Inc. has reported its second quarter 2015 results, posting a year-over-year seven percent revenue increase to…

Stuart Schlossman

Categories

Latest Blog Posts